Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...

Biocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...

Eswara Reddy along with Animesh Kumar (Assistant Drugs Inspector), Biocon Biologics' Associate Vice President L Praveen Kumar, and Synergy ...

The comments came after the Central Bureau of Investigation (CBI) recently arrested five people, including a senior CDSCO official, for all...

The Bengaluru-headquartered company, in a statement, said it is governed by a strong code of conduct and condemns any acts of corruption an...

The guidelines provide a framework for waiver of phase III clinical trials in India based on a commitment to undertake a phase IV trial, th...

The CBI has arrested Joint Drugs Controller S Eswara Reddy, Associate Vice President of Biocon Biologics L Praveen Kumar and three others i...

It was alleged that the accused was trying to exert undue influence on officers of CDSCO (Central Drugs Standard Control Organisation) unde...

With the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the...

A Biocon spokesperson said the company is confident of addressing these observations through procedural enhancements and an appropriate Cor...

Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is ex...

The licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics o...

Biocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a uniqu...

As per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...

The Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...